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This study used data from the Communicable Disease Surveillance Centre’s national HIV database and the Thames Cancer Registry
to assess the risk of cancer in HIV-infected people in southeast England. Among 26 080 HIV-infected men with 158 660 person-years
follow-up, 1851 cancers, and among 7110 HIV-infected women (31 098 person-years), 171 cancers were identified. The standardised
incidence ratio (SIR) for all non-AIDS-defining cancers was significantly increased in HIV-infected men (2.8, 95% confidence interval
(CI) 2.6–3.1) but was nonsignificant in HIV-infected women (1.1, 95% CI 0.8–1.6). Most of the cancers observed were in men
(n¼ 1559) and women (n¼ 127) with AIDS, and among them, the SIR for all non-AIDS-defining cancers was significantly increased in
men (8.2, 95% CI 7.2–9.2) and women (2.8, 95% CI 1.6–4.6). The SIR for all non-AIDS-defining cancers was only just significantly
increased in men with HIV-infection but not AIDS (1.2, 95% CI 1.0–1.5) and was nonsignificant in such women (0.8, 95% CI 0.5–1.2).
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The epidemic of HIV-infection is continuing with nearly 6000 new
HIV-infections reported in 2002, the highest annual total since
1985, and over 50 000 people reported with HIV-infection or AIDS
in the UK by the end of 2001 (Health Protection Agency, 2004).
People with HIV-infection are living longer due to the introduction
of highly active antiretroviral therapies. Cancers and other
illnesses that are related to HIV-infection may therefore become
more common, and this may also be influenced by unknown long-
term effects of the treatment.
By the end of 2001, nearly 70% of people reported to the
Communicable Disease Surveillance Centre (CDSC) with HIV-
infection or AIDS in the UK were reported from London and the
Southeast. This corresponds approximately to the catchment area
of the Thames Cancer Registry (TCR). The aim of this study was to
link data from the cohort of people reported with HIV-infection or
AIDS with data from the TCR to assess the risk of different types of
cancer in HIV-infected people, those with AIDS and those with
HIV-infection but not AIDS. In addition, we aimed to assess the
completeness both of cancer registration in HIV-infected people
and of HIV-infection reporting in people with cancer.
MATERIALS AND METHODS
The CDSC collates information on the diagnosis of HIV-infection
and AIDS in adults in England, Wales and Northern Ireland.
Microbiologists and clinicians report demographic details and how
the infection was probably acquired; the hospital trust from which
the person was reported is also recorded. Names are not recorded
but a soundex code is assigned to each record, comprising the first
letter of the surname and three numbers based on the other letters.
Soundex codes are not unique to one surname but can be used
with other fields to detect duplicate entries. Deaths and AIDS
diagnoses in previously reported people are also reported. The
CDSC also receives information on HIV-infections and AIDS
diagnoses in Scotland from the Scottish Centre for Infection and
Environmental Health.
The TCR collects details of cancers diagnosed in southeast
England in a catchment population of about 14 million people in
London, Surrey, Sussex, Kent, Hertfordshire and Essex; it also
records demographic data, including name, address and postcode.
Patients are flagged in the NHS Central Register, which provides
dates and causes of death. Cancer registration in England and the
HIV/AIDS reporting system are both approved under the section
60 regulations of the Health and Social Care Act. The current study
was approved by the Public Health Laboratory Service Ethics
Committee and the West Midlands Multi-centre Research Ethics
Committee.
The TCR data set in our study comprised the 224 199 cancers
(ICD10 C00-97) that were diagnosed from 1985 to 2001 in people
aged 15– 59 years, who were resident in the TCR catchment area
and had no cancer before 1985. The CDSC data set comprised the
50 182 HIV-infected people who were reported from the UK and
diagnosed by the end of 2001. Both these data sets included date of
birth, sex, soundex code, first initial and date of death. The TCR
data also included second initial and details of the cancer. The
CDSC data also included HIV-diagnosis date, whether the person
had AIDS, AIDS-diagnosis date, when the person was last reported
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alive, and details of AIDS-defining cancers. A variable was created
for whether the HIV-infection was first reported from a hospital in
London, Southeast and Eastern regions, which includes the TCR
catchment area. We then excluded people in the CDSC data whose
first report was outside this area or who had no sex or date or
birth, leaving cohorts of 27 054 men and 7510 women.
The two data sets were matched at the CDSC, accepting matched
records if the date of birth, sex and soundex code were all identical.
We excluded matches if the TCR date of death was before the date
when the CDSC last knew that the person was alive, the dates of
death differed by more than 30 days, or the CDSC date of death
was more than 30 days before the cancer diagnosis date. We also
excluded matches if the CDSC first initial did not match the first or
second initial from the TCR database. Whereas the CDSC database
is person-based, the TCR database is tumour-based. A tumour
record should only match to one person, and we selected the best
match for four tumour records that had each matched to two
different people by reviewing the full patient records. A person
could legitimately match to more than one tumour record, but we
excluded second or third tumours to facilitate the calculation of
person-years. This left 2139 one-to-one matches. We added the
cancer diagnosis date, ICD10 three-digit cancer diagnosis code and
TCR date of death to the CDSC data for people who had matched
to a TCR tumour record.
To calculate person-years at risk, we created entry and exit dates
for each person. For men and women with HIV-infection, we used
whichever was later of the person’s 15th birthday, their HIV-
diagnosis date minus 30 days or 01/01/85, the start of the study
period, as the entry date. For men and women with AIDS, we did
the same but used the AIDS-diagnosis date minus 30 days. We
backdated diagnosis dates so that cancers that may have initiated
an HIV-diagnosis were included. We used the same exit date for
men and women with HIV-infection and AIDS. We replaced 31/12/
01, the end of the study period, with the CDSC date of death if this
was present and before 31/12/01; with the TCR date of death if
present and before 31/12/01; with the cancer diagnosis date if
present; and with the person’s 60th birthday if this was before the
current exit date. We regarded the TCR dates of death as more
accurate because they were supplied by the NHS Central Register.
Before each analysis, we excluded people with exit dates before
01/01/85, entry dates after 31/12/01, exit dates before entry dates,
or the same entry and exit dates. The observed numbers of each
cancer, all cancers and all non-AIDS-defining cancers were then
counted for each cohort during the study period. AIDS-defining
cancers are Kaposi’s sarcoma (KS, ICD10 C46), non-Hodgkin’s
lymphoma (NHL, ICD10 C82-85) and cancer of the cervix uteri
(ICD10 C53). For people with HIV-infection and AIDS, the person-
years at risk in each sex and five-year age-band and period were
multiplied by the incidence rate for each cancer site in southeast
England during the same period. This gave an expected number of
each cancer for each cohort during the study period. For the sexes
separately, we subtracted the observed and expected numbers for
each cancer in those with AIDS from the corresponding numbers
for HIV-infected people to give the numbers for those with HIV-
infection but not AIDS. The observed numbers of each cancer, all
cancers and all non-AIDS-defining cancers were then divided by
the expected number for each cohort and 95% confidence intervals
(CI) calculated for the ratios.
Kaposi’s sarcoma is very rare in young people without HIV-
infection. To assess completeness of reporting of people with HIV-
infection, we reviewed the proportion of KS in the TCR data that
matched to a person in the CDSC data reported from anywhere in
the UK. To assess completeness of cancer registration in HIV-
infected people, we reviewed the proportion of people from the
CDSC data with both an AIDS-defining cancer and a first report
from regions wholly or partly within the TCR catchment area who
matched to a comparable tumour record from the TCR data. We
compared presumptive or definitive KS and Burkitt’s lymphoma or
immunoblastic lymphoma from the CDSC data with, respectively,
KS and NHL from the TCR data. Burkitt’s lymphoma and
immunoblastic lymphoma are classified as NHL by the TCR.
RESULTS
HIV-infection
After making the exclusions based on entry and exit dates, the
analysis included 26 080 HIV-infected men who contributed
158 660 person-years and 1851 cancers. The SIR for all cancers
was 11.5 (95% CI 10.9–12.0), and the SIR for non-AIDS-defining
cancers was 2.8 (95% CI 2.6–3.1) (Table 1). The SIR was
significantly decreased for cutaneous malignant melanoma
(CMM), and significantly increased for 13 cancer sites: anus and
anal canal, liver, bronchus and lung, other skin, KS, nerves and soft
tissue, secondary lymph node, secondary other sites, site unknown,
Hodgkin’s disease, NHL, leukaemias, and other lymphoid haema-
topoietic. The highest SIR was for KS (237, 95% CI 221–253).
The analysis included 7110 HIV-infected women who contrib-
uted 31 098 person-years and 171 cancers. The SIR for all cancers
(5.0, 95% CI 4.2–5.8) was lower than in HIV-infected men, and the
SIR for non-AIDS-defining cancers (1.1, 95% CI 0.8–1.6) was
nonsignificant (Table 1). There was no cancer site where the SIR
was significantly decreased. In contrast to HIV-infected men, the
SIR was significantly increased at only four cancer sites: KS,
secondary lymph node, NHL, and other lymphoid haematopoietic.
The SIR for KS (774; 95% CI 589–999) was, however, higher in
women than men with HIV-infection.
AIDS
After making the exclusions based on entry and exit dates, this
analysis included 10 522 men with AIDS who contributed 30 221
person-years to the analysis. Nearly 85% (n¼ 1559) of the
observed cancers in HIV-infected men were in men with AIDS.
The SIR for all cancers was 42.3 (95% CI 40.2–44.5), and for non-
AIDS-defining cancers 8.2 (95% CI 7.2– 9.2) (Table 2). The SIR was
significantly increased for 14 cancer sites: anus and anal canal,
liver, bronchus and lung, other skin, KS, nerves and soft tissue,
penis, secondary lymph node, secondary other sites, site unknown,
Hodgkin’s disease, NHL, leukaemias, and other lymphoid haema-
topoietic. There was no cancer site where the SIR was significantly
decreased. The highest SIR was for KS (1082, 95% CI 1008– 1160).
This analysis included 1604 women with AIDS who contributed
4728 person-years to the analysis. Nearly 75% (n¼ 127) of the
observed cancers in HIV-infected women were in women with
AIDS. The SIR for all cancers (21.0, 95% CI 17.5–25.0) was lower
than in men with AIDS, as was the SIR for non-AIDS-defining
cancers (2.8, 95% CI 1.6– 4.6) (Table 2). There were no cancer sites
where the SIR was significantly decreased. In contrast to men with
AIDS, the SIR was significantly increased at only five cancer sites:
other skin, KS, secondary lymph node, NHL, and other lymphoid
haematopoietic. The SIR for KS (4356, 95% CI 3263–5698) was,
however, higher in women than men with AIDS.
HIV-infection but not AIDS
Men with HIV-infection but not AIDS contributed 128 438 person-
years and 292 cancers to the analysis. The SIR for all cancers was
2.3 (95% CI 2.1–2.6), but for non-AIDS-defining cancers the
increase was only marginal (1.2, 95% CI 1.0– 1.5) (Table 3). The
SIR was significantly increased for seven cancer sites: anus and
anal canal, liver, other skin, KS, Hodgkin’s disease, NHL, and
other lymphoid haematopoietic. For multiple myeloma, the SIR
was increased but the confidence interval was very close to
nonsignificance. The SIR was significantly decreased for CMM.
The risk of cancer in HIV-infected people
A Newnham et al
195
British Journal of Cancer (2005) 92(1), 194 – 200& 2005 Cancer Research UK
E
p
id
e
m
io
lo
g
y
The highest SIR was for other lymphoid haematopoietic cancer
(29.3, 95% CI 12.7–57.8).
Women with HIV-infection but not AIDS contributed 26 370
person-years and 44 cancers. The SIR for all cancers was 1.5 and
only just significantly increased (95% CI 1.1–2.1), and the SIR for
non-AIDS-defining cancers was only 0.8 (95% CI 0.5–1.2)
(Table 3). The SIR was significantly increased for three cancer
sites: KS, NHL, and other lymphoid haematopoietic. There was no
site where the SIR was significantly decreased. The highest SIR was
for KS (93.7, 95% CI 34.4– 204).
Completeness of ascertainment
There were 1251 cases of KS in the TCR data and 1017 (81%) had a
valid match to a person in the CDSC data reported from anywhere
in the UK. This included 11 matches where KS was the second or
third tumour. Matched cases (94%, n¼ 954) were more likely than
unmatched cases (88%, n¼ 207) to be in men. The matched group
was also younger than the unmatched group: for example, 94%
(n¼ 960) of the matched group were aged under 50 years
compared with 87% (n¼ 203) of the unmatched group. Matched
cases were also more likely to have died by the end of the study
period (69%, n¼ 699) than unmatched cases (44%, n¼ 103).
There were 2079 people from the CDSC data with presumptive
or definitive KS and a first report from a region located wholly or
partly within the TCR catchment area and 648 (31%) had a valid
match to a KS record in the TCR data. This included six matches
where the KS from the TCR data was the second or third tumour.
There were 516 people from the CDSC data with Burkitt’s
lymphoma or immunoblastic lymphoma and a first report from
a region located wholly or partly within the TCR catchment area,
and 228 (44%) had a valid match to an NHL record from the TCR
data. This included matches involving two cases of NHL from the
TCR data that were second or third tumours.
DISCUSSION
This study used data from the national database of HIV-infected
people and a regional cancer registry to assess the risk of cancer in
HIV-infected people in the TCR area, which has the highest
number of people reported with HIV-infection in England. Despite
Table 1 Standardised incidence ratios for cancers (ICD10 C00-97) in men and women with HIV-infection in southeast England. Cancer sites with no
observed cancers in men or women are not included in the table
Men Women All
Obs SIR LCI UCI Obs SIR LCI UCI Obs SIR LCI UCI
Oral (C01–10,14) 5 1.0 0.3 2.3 1 2.5 0.1 14.0 6 1.1 0.4 2.3
Nasopharynx (C11) 3 4.1 0.8 11.9 1 17.1 0.4 95.2 4 5.0 1.4 12.8
Oesophagus (C15) 2 0.5 0.1 1.8 0 0.0 2 0.5 0.1 1.8
Stomach (C16) 2 0.4 0.1 1.6 0 0.0 2 0.4 0.1 1.5
Small intestine (C17) 2 3.8 0.5 13.6 0 0.0 2 3.4 0.4 12.4
Colorectal (C18–20) 12 0.8 0.4 1.4 2 1.5 0.2 5.4 14 0.9 0.5 1.5
Anus and anal canal (C21) 17 25.1 14.6 40.2 1 9.7 0.2 53.9 18 23.1 13.7 36.5
Liver (C22) 13 5.9 3.1 10.1 0 0.0 13 5.6 3.0 9.6
Pancreas (C25) 3 0.8 0.2 2.4 0 0.0 3 0.8 0.2 2.3
Other digestive (C26) 1 3.3 0.1 18.1 0 0.0 1 3.1 0.1 17.0
Nasal cavity (C30,31) 1 1.8 0.05 10.1 0 0.0 1 1.7 0.04 9.4
Larynx (C32) 5 2.1 0.7 4.9 0 0.0 5 2.0 0.7 4.8
Bronchus, lung (C33,34) 38 2.3 1.6 3.2 1 1.0 0.02 5.4 39 2.2 1.6 3.1
Thymus, heart (C37,38) 1 1.7 0.04 9.4 0 0.0 1 1.6 0.04 8.7
Bone (C40,41) 1 1.0 0.03 5.5 0 0.0 1 0.9 0.02 4.9
Skin melanoma (C43) 2 0.2 0.03 0.8 0 0.0 2 0.2 0.02 0.6
Other skin malignant (C44) 68 20.6 16.0 26.2 2 7.2 0.9 26.1 70 19.6 15.3 24.8
Kaposi’s sarcoma (C46) 872 236.5 221.1 252.7 59 774.2 589.4 998.7 931 247.4 231.8 263.8
Nerves, soft tissue (C47,49) 6 3.6 1.3 7.9 0 0.0 6 3.1 1.2 6.8
Breast (C50) 12 0.8 0.4 1.4 12 0.8 0.4 1.4
Cervix uteri (C53) 3 1.0 0.2 2.9 3 1.0 0.2 2.9
Ovary (C56) 2 1.0 0.1 3.7 2 1.0 0.1 3.7
Penis (C60) 3 3.9 0.8 11.5 3 3.9 0.8 11.5
Prostate (C61) 5 0.9 0.3 2.0 5 0.9 0.3 2.0
Testis (C62) 19 1.1 0.6 1.7 19 1.1 0.6 1.7
Kidney (C64,65) 6 1.2 0.4 2.6 0 0.0 6 1.1 0.4 2.5
Bladder (C67) 3 0.5 0.1 1.5 0 0.0 3 0.5 0.1 1.5
Meninges, brain and spinal cord (C70–72) 9 1.1 0.5 2.0 0 0.0 9 1.0 0.4 1.8
Thyroid (C73) 1 0.7 0.02 3.6 0 0.0 1 0.4 0.01 2.3
Secondary lymph node (C77) 31 34.0 23.1 48.3 3 35.0 7.2 102.1 34 34.1 23.6 47.6
Secondary respiratory/digestive (C78) 2 1.1 0.1 4.1 0 0.0 2 1.0 0.1 3.7
Secondary other sites (C79) 8 6.5 2.8 12.9 0 0.0 8 6.0 2.6 11.9
Site unknown (C80) 54 17.4 13.0 22.6 1 2.9 0.1 16.4 55 15.9 12.0 20.7
Hodgkin’s disease (C81) 36 6.1 4.3 8.5 2 2.3 0.3 8.3 38 5.6 4.0 7.7
Non-Hodgkin’s lymphoma (C82–85) 571 40.9 37.7 44.4 75 61.5 48.4 77.1 646 42.6 39.4 46.0
Multiple myeloma (C90) 5 2.4 0.8 5.6 1 7.5 0.2 41.7 6 2.7 1.0 5.9
Leukaemias (C91–95) 18 2.6 1.6 4.2 1 1.4 0.03 7.6 19 2.5 1.5 3.9
Other lymphoid, haematopoietic (C96) 26 75.5 49.3 110.6 4 173.7 47.3 444.7 30 81.6 55.1 116.5
All non-AIDS-defining cancers 408 2.8 2.6 3.1 34 1.1 0.8 1.6 442 2.5 2.3 2.8
All cancers 1851 11.5 10.9 12.0 171 5.0 4.2 5.8 2022 10.3 9.9 10.8
Bold values indicate cancer sites where the 95% confidence interval does not include one.
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including about 33 000 HIV-infected people, there were few
cancers in women. Although much smaller than certain linkage
studies of people with AIDS (Goedert et al, 1998; Frisch et al, 2001;
Gallagher et al, 2001; Mbulaiteye et al, 2003), our cohorts were
larger than other studies of HIV-infected people (Cooksley et al,
1999; Grulich et al, 2002; Allardice et al, 2003).
False matches would mean that observed cancers were over-
estimated, whereas too few true matches would mean the reverse.
Assessing the accuracy of matching is difficult because there is no
gold standard and it is subject to the degree of completeness of the
databases. Nearly 20% of KS from the TCR data did not match to a
person reported to the CDSC from anywhere in the UK. Assuming
that these tumours were correctly classified as KS, they could be in
people without HIV-infection, HIV-infected people who were
reported to the CDSC but that we failed to match with their tumour
record, or HIV-infected people who were not reported to the
CDSC. The first explanation is unlikely as KS in younger people
without HIV-infection is very rare. The second explanation is
possible, and we would have underestimated observed cancers
and, therefore, SIRs if this were the case. The third explanation is
also possible. Under-reporting for AIDS has been estimated to be
about 10% (Evans, 1995), and the TCR may be aware of cases of
which the CDSC is unaware because the CDSC and the TCR obtain
details of cases via separate mechanisms. Staff from the TCR
retrieve information from patient notes, whereas the CDSC relies
on reports from clinicians. Any incompleteness of reporting of
HIV-infected people would mean that we underestimated observed
and expected cancers.
We matched less than one-third of people from the CDSC data
with presumptive or definitive KS and a first report from a
region located wholly or partly within the TCR catchment area to a
TCR KS record. This suggests incompleteness of registration of
KS by the TCR. The case definition of KS used by the CDSC
and the TCR are similar, but sexually transmitted infection clinic
notes may not be available to staff who are registering cancers,
which could lead to diagnoses made in this setting being missed by
the cancer registry. Incompleteness of cancer registration may
vary by site and be higher for KS than other sites. We matched a
higher, but still fairly low, proportion (44%) of people from the
CDSC data with Burkitt’s lymphoma or immunoblastic lymp-
homa and a first report from a region located wholly or partly
within the TCR catchment area to a TCR NHL record. The
overall completeness of registrations 5 years after diagnosis
has been estimated as 92% (Bullard et al, 2000), but failure to
register cancers may be more likely in HIV-infected people than
the general population. Overall, any incompleteness of cancer
Table 2 Standardised incidence ratios for cancers (ICD10 C00-97) in men and women with AIDS in southeast England. Cancer sites with no observed
cancers in men or women are not included in the table
Men Women All
Obs SIR LCI UCI Obs SIR LCI UCI Obs SIR LCI UCI
Oral (C01–10,14) 4 3.2 0.9 8.1 1 17.0 0.4 95.0 5 3.8 1.2 8.8
Nasopharynx (C11) 1 6.2 0.2 34.5 0 0.0 1 5.8 0.1 32.5
Oesophagus (C15) 1 1.0 0.02 5.5 0 0.0 1 1.0 0.02 5.3
Stomach (C16) 2 1.8 0.2 6.6 0 0.0 2 1.8 0.2 6.3
Small intestine (C17) 1 8.0 0.2 44.7 0 0.0 1 7.4 0.2 41.3
Colorectal (C18–20) 5 1.4 0.4 3.2 1 4.0 0.1 22.4 6 1.5 0.6 3.4
Anus and anal canal (C21) 7 42.8 17.2 88.1 0 0.0 7 38.1 15.3 78.5
Liver (C22) 4 7.6 2.1 19.5 0 0.0 4 7.4 2.0 18.8
Pancreas (C25) 2 2.2 0.3 8.0 0 0.0 2 2.1 0.3 7.7
Other digestive (C26) 1 13.4 0.3 74.4 0 1 13.4 0.3 74.4
Nasal cavity (C30,31) 1 7.9 0.2 44.0 0 1 7.9 0.2 44.0
Larynx (C32) 2 3.3 0.4 11.8 0 0.0 2 3.2 0.4 11.6
Bronchus, lung (C33,34) 25 6.0 3.9 8.9 1 5.0 0.1 27.8 26 6.0 3.9 8.8
Thymus, heart (C37,38) 1 7.9 0.2 43.8 0 1 7.9 0.2 43.8
Bone (C40,41) 1 5.3 0.1 29.3 0 0.0 1 4.8 0.1 26.5
Skin melanoma (C43) 1 0.5 0.01 2.9 0 0.0 1 0.4 0.01 2.4
Other skin malignant (C44) 55 71.3 53.7 92.8 2 41.6 5.1 150.3 57 69.5 52.7 90.1
Kaposi’s sarcoma (C46) 787 1082.0 1007.7 1160.3 53 4356.0 3262.9 5697.7 840 1135.9 1060.3 1215.3
Nerves, soft tissue (C47,49) 5 14.9 4.9 34.9 0 0.0 5 13.4 4.3 31.2
Breast (C50) 1 0.4 0.01 2.0 1 0.4 0.01 2.0
Cervix uteri (C53) 1 2.1 0.1 11.4 1 2.1 0.1 11.4
Penis (C60) 2 11.1 1.3 40.0 2 11.1 1.3 40.0
Prostate (C61) 1 0.6 0.02 3.4 1 0.6 0.02 3.4
Testis (C62) 6 1.9 0.7 4.0 6 1.9 0.7 4.0
Kidney (C64,65) 2 1.7 0.2 6.0 0 0.0 2 1.6 0.2 5.8
Bladder (C67) 1 0.7 0.02 4.0 0 0.0 1 0.7 0.02 3.9
Meninges, brain and spinal cord (C70–72) 5 2.8 0.9 6.5 0 0.0 5 2.6 0.8 6.0
Secondary lymph node (C77) 29 135.4 90.7 194.4 3 195.7 40.4 571.7 32 139.4 95.4 196.8
Secondary respiratory/digestive (C78) 2 4.7 0.6 16.8 0 0.0 2 4.3 0.5 15.4
Secondary other sites (C79) 6 20.3 7.4 44.2 0 0.0 6 19.0 7.0 41.4
Site unknown (C80) 51 68.4 50.9 89.9 1 16.0 0.4 89.1 52 64.3 48.0 84.4
Hodgkin’s disease (C81) 16 15.0 8.6 24.4 0 0.0 16 13.4 7.7 21.7
Non-Hodgkin’s lymphoma (C82–85) 502 163.5 149.5 178.4 58 279.8 212.5 361.7 560 170.8 157.0 185.6
Multiple myeloma (C90) 0 0.0 1 38.4 1.0 214.1 1 1.8 0.05 10.2
Leukaemias (C91–95) 12 8.1 4.2 14.2 1 9.0 0.2 50.1 13 8.2 4.4 14.0
Other lymphoid, haematopoietic (C96) 18 250.2 148.3 395.4 3 820.1 169.1 2396.1 21 277.8 172.0 424.6
All non-AIDS-defining cancers 270 8.2 7.2 9.2 15 2.8 1.6 4.6 285 7.4 6.6 8.3
All cancers 1559 42.3 40.2 44.5 127 21.0 17.5 25.0 1686 39.3 37.4 41.2
Bold values indicate cancer sites where the 95% confidence interval does not include one.
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registration would mean that we underestimated observed cancers
and SIRs.
During the overall analyses and the assessment of the
completeness of cancer registration in HIV-infected people, we
excluded people from the CDSC data whose first report was not
from a region located wholly or partly within the TCR catchment
area, that is not from London, Southeast and Eastern Regions. As
the Southeast and Eastern Regions extend beyond the TCR
catchment area, the cohorts will have included people from
outside the TCR catchment area. Some of the apparent incomple-
teness of registration of KS and NHL from the CDSC data by the
TCR may, therefore, be explained by their registration at other
regional cancer registries. Overall, the inclusion of people from
outside the TCR catchment area will have meant that person-years
at risk and expected cancers were overestimated and SIRs were
underestimated.
To examine the robustness of our estimates, we created different
entry and exit dates. The SIRs and profile of cancers with
significantly increased or decreased SIRs were generally similar
with entry dates created using the HIV- or AIDS-diagnosis date
minus 30 days or the HIV- or AIDS-diagnosis date itself.
Two other exit dates were created by using the CDSC last known
alive date instead of the TCR and CDSC dates of death, and by
omitting the steps involving the dates of death and only using the
cancer diagnosis date and the person’s 60th birthday. Observed
cancers were the same for each exit date because the penultimate
step was always to replace the current date with the cancer
diagnosis date if present, but total person-years at risk and,
therefore, expected cancers and SIRs varied. Expected cancers were
generally highest and SIRs were generally lowest when exit dates
were based only on cancer diagnosis dates and 60th birthdays. For
HIV-infected men, expected cancers were not consistently lower
for exit dates based on last known alive dates or dates of death. For
HIV-infected women, expected cancers were generally lowest and
SIRs were generally highest for exit dates based on last known alive
dates. For men and women with AIDS, expected cancers were
generally lowest and SIRs were generally highest for exit dates
based on dates of death rather than last known alive dates. This
was because a smaller proportion of people with AIDS than all
HIV-infected people had a last known alive date. Although it
seemed reasonable to use exit dates based on dates of death for this
study, it may be more accurate to combine last known alive dates
and dates of death in a single exit date in future analyses.
Comparing our results with results from other studies is
complicated by different methods and time periods used. Results
from other studies were also usually presented for men and women
combined. The introduction of highly active antiretroviral therapy
in 1996 may also have altered the risk of some cancers. It has been
suggested that people may cease to be at risk of KS once immune
function has been improved by therapy (Ledergerber et al, 1999),
and there was a significant decrease in the risk of KS and NHL but
not other cancers from 1992–1996 to 1997–1999 when data from
23 prospective studies were combined (International Collaboration
on HIV and Cancer, 2000). Conversely, people may now survive
Table 3 Standardised incidence ratios for cancers (ICD10 C00-97) in men and women with HIV-infection but not AIDS in southeast England. Cancer
sites with no observed cancers in men or women are not included in the table
Men Women All
Obs SIR LCI UCI Obs SIR LCI UCI Obs SIR LCI UCI
Oral (C01–10,14) 1 0.3 0.01 1.4 0 0.0 1 0.2 0.01 1.3
Nasopharynx (C11) 2 3.5 0.4 12.5 1 20.6 0.5 114.8 3 4.8 1.0 14.0
Oesophagus (C15) 1 0.3 0.01 1.9 0 0.0 1 0.3 0.01 1.8
Small intestine (C17) 1 2.5 0.1 13.7 0 0.0 1 2.2 0.1 12.5
Colorectal (C18–20) 7 0.6 0.3 1.3 1 0.9 0.02 5.1 8 0.7 0.3 1.3
Anus and anal canal (C21) 10 19.5 9.3 35.8 1 12.0 0.3 66.8 11 18.4 9.2 33.0
Liver (C22) 9 5.3 2.4 10.1 0 0.0 9 5.1 2.3 9.7
Pancreas (C25) 1 0.4 0.01 2.1 0 0.0 1 0.3 0.01 1.9
Larynx (C32) 3 1.7 0.3 4.9 0 0.0 3 1.6 0.3 4.8
Bronchus, lung (C33,34) 13 1.1 0.6 1.8 0 0.0 13 1.0 0.5 1.7
Skin melanoma (C43) 1 0.1 0.004 0.8 0 0.0 1 0.1 0.003 0.6
Other skin malignant (C44) 13 5.2 2.7 8.8 0 0.0 13 4.7 2.5 8.1
Kaposi’s sarcoma (C46) 85 28.7 22.9 35.5 6 93.7 34.4 203.9 91 30.1 24.2 36.9
Nerves, soft tissue (C47,49) 1 0.8 0.02 4.2 0 0.0 1 0.7 0.02 3.6
Breast (C50) 11 0.9 0.4 1.6 11 0.9 0.4 1.6
Cervix uteri (C53) 2 0.8 0.1 2.9 2 0.8 0.1 2.9
Ovary (C56) 2 1.2 0.2 4.5 2 1.2 0.2 4.5
Penis (C60) 1 1.7 0.04 9.5 1 1.7 0.04 9.5
Prostate (C61) 4 0.9 0.3 2.4 4 0.9 0.3 2.4
Testis (C62) 13 0.9 0.5 1.5 13 0.9 0.5 1.5
Kidney (C64,65) 4 1.1 0.3 2.7 0 0.0 4 1.0 0.3 2.5
Bladder (C67) 2 0.5 0.1 1.6 0 0.0 2 0.4 0.1 1.6
Meninges, brain and spinal cord (C70–72) 4 0.6 0.2 1.5 0 0.0 4 0.5 0.1 1.4
Thyroid (C73) 1 0.8 0.02 4.6 0 0.0 1 0.5 0.01 2.8
Secondary lymph node (C77) 2 2.9 0.3 10.4 0 0.0 2 2.6 0.3 9.4
Secondary other sites (C79) 2 2.2 0.3 7.8 0 0.0 2 2.0 0.2 7.2
Site unknown (C80) 3 1.3 0.3 3.7 0 0.0 3 1.1 0.2 3.3
Hodgkin’s disease (C81) 20 4.2 2.5 6.4 2 2.7 0.3 9.8 22 4.0 2.5 6.0
Non-Hodgkin’s lymphoma (C82–85) 69 6.3 4.9 8.0 17 16.8 9.8 26.9 86 7.2 5.8 8.9
Multiple myeloma (C90) 5 3.2 1.0 7.4 0 0.0 5 3.0 1.0 6.9
Leukaemias (C91–95) 6 1.1 0.4 2.4 0 0.0 6 1.0 0.4 2.2
Other lymphoid, haematopoietic (C96) 8 29.3 12.7 57.8 1 51.6 1.3 287.7 9 30.8 14.1 58.5
All non-AIDS-defining cancers 138 1.2 1.0 1.5 19 0.8 0.5 1.2 157 1.2 1.0 1.4
All cancers 292 2.3 2.1 2.6 44 1.5 1.1 2.1 336 2.2 2.0 2.4
Bold values indicate cancer sites where the 95% confidence interval does not include one.
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longer to develop a cancer associated with other risk factors. The
risk of lung cancer increased between 1992–1995 and 1996–1999
in a cohort of about 77 000 HIV-infected men identified through
French hospitals (Herida et al, 2003).
Studies have been largely consistent for people with AIDS. We
observed an increased risk of lung cancer, Hodgkin’s disease and
all non-AIDS-defining cancers in people with AIDS in southeast
England compared with the general population. This was
consistent with studies linking cancer registry data with data from
people who were diagnosed with AIDS in the USA from 1978 to
1996 (Frisch et al, 2001) and Italy from 1985 to 1998 (Dal Maso
et al, 2003), and people who were notified up to 1999 to the
Australian HIV and AIDS databases (Grulich et al, 2002). We also
observed an increased risk of anal cancer and leukaemia consistent
with the studies from Italy and the USA, an increased risk of
cancer of nerves and soft tissues consistent with the studies from
Australia and the USA, and an increased risk of liver cancer and
cancer of the oral cavity consistent with the study from the USA.
We found an increased risk of penile cancer in men with AIDS
consistent with the study from the USA, but we only observed two
such cancers.
Results for non-AIDS-defining cancers for HIV-infected people
were not as consistent. Even so, we found an increased risk of liver
cancer, lung cancer and all non-AIDS-defining cancers in HIV-
infected people, which was consistent with a Scottish study linking
cancer registry data with data from people with HIV-infection and/
or AIDS from 1981 to 1996 (Allardice et al, 2003). We also found an
increased risk of anal cancer, cancer of nerves and soft tissues,
Hodgkin’s disease, leukaemia and all non-AIDS-defining cancers
consistent with an increased risk of these cancers in HIV-infected
people in Australia (Grulich et al, 2002). The increased risk of
Hodgkin’s disease was also consistent with an increased risk in HIV-
infected men in Texas that was observed when cancer registry data
from 1975 to 1994 were linked with data from people with HIV-
infection and/or AIDS from 1981 to 1994 (Cooksley et al, 1999).
The increased risk of other skin cancer in HIV-infected people
was higher in this study than other studies (Cooksley et al, 1999;
Allardice et al, 2003). This may suggest that some non-KS skin
cancers in this study were actually KS. We also found that HIV-
infected men had a decreased risk of CMM. This could indicate
that HIV-infection protects against CMM but may be more likely
to indicate that CMMs were under ascertained or misclassified as
KS. Any resulting increase in the number of KS was probably
balanced by KS that were wrongly assigned as other skin cancers.
Misclassification of Hodgkin’s disease and NHL may also partly
explain the increased risk of other lymphoid haematopoietic
cancer in men and women with HIV-infection, AIDS, and HIV-
infection but not AIDS in this study.
We also assessed the risk of cancer in HIV-infected people who
had not had an AIDS diagnosis reported. The excess of KS and
NHL in these men and women is an artefact. If the matches were
correct, the people involved should have been reported with AIDS
and not included in this part of the analysis, although any other
cancers in these people were excluded when we excluded second
and third tumours. Most of the increased risk in HIV-infected
people in this study was related to AIDS, which suggests that, so
far, most cancers in HIV-infected people have been associated with
AIDS-related immunosuppression. The risk only remained in-
creased for anal cancer, liver cancer, other skin cancer, Hodgkin’s
disease, and other lymphoid haematopoietic cancer, and the risk of
all non-AIDS-defining cancers was only just increased in HIV-
infected men without AIDS. The increased risk of liver cancer may
have been due to the comparison of cohorts of people with a high
and low prevalence of hepatitis B infection. Chronic infection with
hepatitis B causes liver cancer. Prevalence is much higher in Africa
than Western Europe (International Agency for Research on
Cancer, 1994), and over 70% of new HIV-diagnoses in the UK
ascribed to heterosexual transmission in 2001 were in people from,
or who had acquired their infection in, Africa (Communicable
Disease Surveillance Centre, 2002).
Other groups assessed the risk of cancer before AIDS by linking
data from cancer registries and AIDS registers and examining
periods from 5 years to 6 months before AIDS (Frisch et al, 2001;
Grulich et al, 2002; Dal Maso et al, 2003). The risk of anal cancer
and Hodgkin’s disease was increased before AIDS in Italy and
Australia, similar to this study, and the risk of all non-AIDS-
defining cancers was increased in Italy (Grulich et al, 2002; Dal
Maso et al, 2003). It has, however, been suggested that this method
will under ascertain pre-AIDS cancers because some HIV-infected
people with cancer will not survive to AIDS (Engels et al, 2002). In
Australia, when the analysis included people with HIV-infection
who had not progressed to AIDS as well as people with AIDS from
the date of their HIV-infection to 5 years before AIDS, the risk of
liver cancer was increased similar to this study (Grulich et al,
2002). In Australia, cancer registry data were also linked with data
from people from the National HIV Database who were followed to
6 months before AIDS, cancer, death, or the end of the study
period (Li et al, 2002), but only anal and testicular cancer had a
significantly increased risk.
This study has established the feasibility of assessing the risk of
cancer in HIV-infected adults using data from the CDSC and a UK
regional cancer registry. Factors that could have affected the
estimates of observed and expected cancers have been identified
and should be further explored in any future analyses. Future
analyses could also involve stratification of the cohort by
subgroups based on route of acquisition, ethnicity or country of
birth as well as examine different periods to explore possible
effects on cancer risk of highly active anti-retroviral therapy. This
will also facilitate comparison with the results of studies from
other time periods.
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